Blake Borgeson trims Recursion (RXRX) stake under 10b5-1 plan

Rhea-AI Filing Summary

Recursion Pharmaceuticals director Blake Borgeson sold 220,000 shares of Class A common stock on February 3, 2026 at $4.20 per share. The sale was made under a Rule 10b5-1 trading plan adopted on August 31, 2025. After this transaction, he beneficially owned 6,429,863 shares, held directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Borgeson Blake

(Last) (First) (Middle)

C/O RECURSION PHARMACEUTICALS

41 S. RIO GRANDE STREET

(Street)

SALT LAKE CITY UT 84101

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
RECURSION PHARMACEUTICALS, INC. [ RXRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	02/03/2026		S(1)		220,000	D	$4.2	6,429,863	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 31, 2025.

Remarks:

	/s/ Jonathan Golightly, attorney-in-fact	02/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did the RXRX Form 4 filing disclose about Blake Borgeson?

The Form 4 shows director Blake Borgeson sold 220,000 Class A shares of Recursion Pharmaceuticals at $4.20 per share on February 3, 2026. Following the trade, he directly beneficially owned 6,429,863 shares of the company’s Class A common stock.

At what price were Recursion Pharmaceuticals (RXRX) shares sold in this Form 4?

The reported transaction involved selling 220,000 Class A shares at a price of $4.20 per share. This price is the transaction price disclosed for the February 3, 2026 sale by director Blake Borgeson, as reported in the Form 4 filing.

How many RXRX shares does Blake Borgeson own after this reported sale?

After the reported sale, director Blake Borgeson beneficially owned 6,429,863 shares of Recursion Pharmaceuticals Class A common stock. The Form 4 indicates these shares are held with direct ownership, reflecting his position following the February 3, 2026 transaction.

Was the RXRX insider sale made under a Rule 10b5-1 trading plan?

Yes. The filing notes the sale was made under a Rule 10b5-1 trading plan adopted by Blake Borgeson on August 31, 2025. Such plans pre-schedule trades, allowing insiders to systematically sell shares over time according to predetermined instructions.

Who is the insider involved in this Recursion Pharmaceuticals (RXRX) Form 4?

The insider is Blake Borgeson, identified as a director of Recursion Pharmaceuticals. The Form 4 specifies he is not listed as an officer or 10% owner, and it reports his direct ownership and sale of Class A common stock on February 3, 2026.

What type of security was involved in the RXRX insider transaction?

The transaction involved Class A Common Stock of Recursion Pharmaceuticals. The Form 4 reports a non-derivative transaction coded as a sale, covering 220,000 shares at $4.20 per share, and updates the total directly owned shares to 6,429,863.